Avencell Europe GmbH
Records under this name other than the patents Avencell Europe GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 9 patents it holds.
Showing 1 to 2 of 2 · Back to Avencell Europe GmbH
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,072,079 | An Isolated Human Mesenchymal Stem Cell Expressing a Bispecific Antibody That Binds CD33 and CD3 Lapsed on the fee record Ended Sep 11, 2026 · High confidence | Lapsed on the fee record | Ended Sep 11, 2026 | High confidence |
| US 10,941,202 | An Isolated Human Mesenchymal Stem Cell Expressing a Bispecific Antibody That Binds CD33 and CD3 and Method of Using to Treat Cancer Lapsed on the fee record Ended Mar 9, 2025 · High confidence | Lapsed on the fee record | Ended Mar 9, 2025 | High confidence |